Jason Bednar
Stock Analyst at Piper Sandler
(2.00)
# 3,104
Out of 4,996 analysts
183
Total ratings
35.25%
Success rate
-5.92%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICUI ICU Medical | Maintains: Overweight | $145 → $153 | $118.81 | +28.78% | 2 | Sep 10, 2025 | |
| COO The Cooper Companies | Maintains: Overweight | $105 → $83 | $67.55 | +22.87% | 14 | Aug 28, 2025 | |
| SOLV Solventum | Maintains: Overweight | $87 → $94 | $71.37 | +31.71% | 7 | Aug 8, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $185 → $200 | $184.60 | +8.34% | 10 | Aug 8, 2025 | |
| MASI Masimo | Maintains: Overweight | $200 → $210 | $141.48 | +48.43% | 16 | Aug 6, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $19 | $20.35 | -6.63% | 13 | Aug 1, 2025 | |
| MMSI Merit Medical Systems | Maintains: Overweight | $110 → $105 | $80.20 | +30.92% | 13 | Jul 31, 2025 | |
| ALGN Align Technology | Maintains: Overweight | $250 → $190 | $126.19 | +50.57% | 31 | Jul 31, 2025 | |
| LUNG Pulmonx | Downgrades: Neutral | $9 → $2.5 | $1.74 | +43.68% | 12 | Jul 31, 2025 | |
| NVCR NovoCure | Reiterates: Overweight | $34 | $12.89 | +163.77% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $3.5 | $3.95 | -11.28% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $12.50 | +28.00% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $66.04 | +16.60% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $15.82 | -17.83% | 2 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $2.43 | +85.19% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $249.08 | +6.39% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $4.63 | +29.59% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.11 | +70.32% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $2.46 | +713.01% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $441.12 | -15.67% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $72.46 | +31.11% | 1 | Apr 19, 2023 |
ICU Medical
Sep 10, 2025
Maintains: Overweight
Price Target: $145 → $153
Current: $118.81
Upside: +28.78%
The Cooper Companies
Aug 28, 2025
Maintains: Overweight
Price Target: $105 → $83
Current: $67.55
Upside: +22.87%
Solventum
Aug 8, 2025
Maintains: Overweight
Price Target: $87 → $94
Current: $71.37
Upside: +31.71%
Becton, Dickinson and Company
Aug 8, 2025
Maintains: Neutral
Price Target: $185 → $200
Current: $184.60
Upside: +8.34%
Masimo
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $141.48
Upside: +48.43%
Envista Holdings
Aug 1, 2025
Maintains: Neutral
Price Target: $17 → $19
Current: $20.35
Upside: -6.63%
Merit Medical Systems
Jul 31, 2025
Maintains: Overweight
Price Target: $110 → $105
Current: $80.20
Upside: +30.92%
Align Technology
Jul 31, 2025
Maintains: Overweight
Price Target: $250 → $190
Current: $126.19
Upside: +50.57%
Pulmonx
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $1.74
Upside: +43.68%
NovoCure
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $12.89
Upside: +163.77%
May 8, 2025
Maintains: Neutral
Price Target: $4.5 → $3.5
Current: $3.95
Upside: -11.28%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $12.50
Upside: +28.00%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $66.04
Upside: +16.60%
Apr 23, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $15.82
Upside: -17.83%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.43
Upside: +85.19%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $249.08
Upside: +6.39%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $4.63
Upside: +29.59%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $4.11
Upside: +70.32%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $2.46
Upside: +713.01%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $441.12
Upside: -15.67%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $72.46
Upside: +31.11%